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OBJECTIVE—Insulin detemir lacks the usual propensity for insulin to cause weight gain. We
investigated whether this effect was a result of reduced energy intake and/or increased energy
expenditure.
RESEARCH DESIGN AND METHODS—A 32-week, randomized crossover design trial
was undertaken in 23 patients with type 1 diabetes. Patients on a basal-bolus regimen (with
insulin aspart as the bolus insulin) were randomly assigned to insulin detemir or NPH insulin as
a basal insulin for 16 weeks, followed by the other basal insulin for 16 weeks. At the end of each
16-week period, total energy expenditure, resting energy expenditure, diet-induced thermo-
genesis, activity energy expenditure, energy intake, weight change, glycemic control, hypogly-
cemic episodes, and hormones that affect satiety and fuel partitioning were measured.
RESULTS—After 16 weeks, weight change was 20.69 6 1.85 kg with insulin detemir and
+1.7 6 2.46 kg with NPH insulin (P , 0.001). Total energy intake was signiﬁcantly less with
insulin detemir (2,016 6 501 kcal/day) than with NPH insulin (2,181 6 559 kcal/day) (P =
0.026). There was no signiﬁcant difference in any measure of energy expenditure, HbA1c per-
centage, or number of hypoglycemic episodes. Leptin was lower and resistin was higher with
insulin detemir compared with NPH insulin (P = 0.039, P = 0.047). After the meal, ghrelin and
pancreatic polypeptide levels (P = 0.002, P = 0.001) were higher with insulin detemir.
CONCLUSIONS—The reduced weight gain with insulin detemir compared with NPH in-
sulin is attributed to reduced energy intake rather than increased energy expenditure. This may
be mediated by a direct or indirect effect of insulin detemir on the hormones that control satiety.
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E
xogenous insulin-replacement ther-
apy remains the most effective treat-
ment for hyperglycemia in type 1
diabetic and poorly controlled type 2
diabetic patients, but it regularly results
in excessive weight gain. The Diabetes
Control and Complications Trial showed
that insulin-associated weight gain (1)
was greater in patients receiving intensiﬁed
interventionthaninthosereceivingconven-
tional intervention (5.1 vs. 3.7 kg, P ,
0.0001, during ﬁrst 12 months of therapy).
In type 1 diabetes, adherence to
prescribed insulin regimens may be
compromised by a desire to avoid weight
gain. The problem of insulin omission was
conﬁrmed in a U.K. study (2) of 65 young
subjects with type 1 diabetes. A total of
30% of the women admitted to having
underdosed insulin to manipulate their
weight, whereas 45% of women who de-
veloped microvascular complications had
intentionally misused insulin to prevent
weight gain.
Not all types of insulin treatment are
equally prone to causing weight gain.
Treatment with insulin detemir, a novel
basalinsulinanalog,hasbeenconsistently
shown to cause no weight gain in patients
withtype1diabetes,comparedwithNPH
insulin (3), and lower weight gain in pa-
tients with type 2 diabetes. A myristic
fatty-acidchainattachedtotheB-terminal
of the insulin molecule allows reversible
albumin binding and prolonged resi-
dence time in the subcutaneous depot
and in the circulation (4).
The mechanism(s) underlying the
apparent weight advantage of insulin
detemir has not been identiﬁed. Elucida-
tion of this mechanism(s) could provide
valuable insights into the ways in which
insulin treatment causes weight gain in
diabetes. Such knowledge also might en-
able the future development of insulin
analogs with even greater metabolic ad-
vantages.
RESEARCH DESIGN AND
METHODS—Thisstudywasregistered
with clinicaltrials.gov (NCT00509925)
and was approved by the U.K. Medicines
and Healthcare Products Regulatory
Agency (Eudract 2006-003060-59), the
East Kent Research Ethics Committee,
and the University of Surrey Research
Ethics Committee. The study was a 32-
week, single-center, open-labeled, ran-
domized crossover trial. Twenty-three
patients with type 1 diabetes on a basal-
bolus regimen were recruited (male-to-
female ratio 14 to 9, [mean 6 SE] average
age 38.8 6 2.17 years, average weight
81.9 6 2.21 kg, BMI 28 6 3.6 kg/m
2,
duration of diabetes 19.95 6 2.09 years,
and HbA1c 8.2 6 0.22%). One patient
didnotcompletethetrialfor personalrea-
sons. Patients were randomly assigned to
receive either insulin detemir or NPH in-
sulin as a basal insulin. After 16 weeks of
treatment, subjects were switched to the
other basal insulin. Insulin aspart was
used throughout as the bolus insulin.
Both insulin detemir and NPH insulin
were administered once or twice daily,
according to individual needs and pre-
breakfast and predinner glucose targets
(aiming for ,6.0 mmol/L without signiﬁ-
canthypoglycemia).Therewere5patients
on twice-daily insulin detemir and 17
patients on once-daily insulin detemir.
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ORIGINAL ARTICLEDuring the trial, subjects attended the
hospital for eight planned visits, and the
investigator was in contact with the pa-
tients by telephone at least 10 times.
Inclusion criteria was type 1 diabetes du-
ration .12 months, on a basal-bolus in-
sulin regimen for .3 months, age .18
years, BMI ,40 kg/m
2,a n dH b A 1c be-
tween 7.0 and 11.0%. Exclusion criteria
included anticipated change in medica-
tions known to interfere with glucose
metabolism, proliferative retinopathy, re-
current major hypoglycemia or hypogly-
cemic unawareness, impaired hepatic or
renal functions, pregnancy, and uncon-
trolled hypertension. Body weight, fat
mass, fat-free mass (measured on a Tanita
BC-418 segmental body composition an-
alyzer), insulin doses, hypoglycemic epi-
sodes, and home blood glucose readings
were recorded at baseline and at weeks 8,
14, and 16 of each 16-week treatment pe-
riod. During week 14 of both treatment
periods, patients attended after an over-
n i g h tf a s t .R e s t i n ge n e r g ye x p e n d i t u r e
for 30 min was measured by indirect cal-
orimetry (Medgraphics CCM Express). A
fasting blood sample was taken for the
measurement of hormones and adipo-
kines. A fasting urine sample was col-
lected for baseline urine enrichment for
the calculation of total energy expenditure,
using double-labeled water. Subjects
thenweregivenastandard,ﬁber-free,liq-
uid mixed meal (500 kcal, 60 g carbohy-
drate, 21 g lipids, and 19 g protein), and
multiple measurements of energy expen-
diture were made by indirect calorimetry
and hormonal responses measured for
3 h. Blood samples were taken at over
180 min for glucagon-like peptide-1,
ghrelin,pancreaticpolypeptide,andpep-
tide YY.
Double-labeled water (0.174 g/kg body
wt
18O and 0.07 g/kg body wt
2H2O) then
was administered orally to measure total
energy expenditure. Patients were pro-
vided with urine-collection bottles and a
log sheet to monitor the time and date of
collections for 14 days. To measure appe-
tite, subjects were provided with a large
container of a standardized pasta meal
(1,230 g, 1,740 kcal) and were asked to
eat until they felt comfortably full. The
meal was weighed before and after pa-
tients had eaten and the calorie intake
was calculated. At the end of the visit, an
Actiheartmonitor(CamNtech,Cambridge,
U.K.) was ﬁtted to record their activity en-
ergy expenditure for the next 5 days. Pa-
tients also were provided with a diary to
record their 7-day food intake during the
following week. They were taught how to
accurately complete a record of everything
they ate. During week 16 of each treat-
ment period, patients attended the hos-
pital with their food diaries, Actihearts,
and 14-day urine samples.
Analytical methods
For measurement of total energy expen-
diture, the urine samples were analyzed
in duplicate for H2
18Oa n d
2H2Oo naD
plus XP isotope ratio mass spectrometer
(Thermo Scientiﬁc, Bremen Germany)
with a Gasbench II inlet system and a
GCpal auto sampler (CTC Analytics, Pre-
search, Basingstoke, U.K.).
2H2 enrich-
ment was measured using a platinum
catalyst rod. The sample tubes were
capped and ﬂushed (100 mL/min) with
the equilibration gas, 5% H2 in helium,
and incubated for a minimum of 40 min
at22.5°C.Theisotopicenrichmentof
18O
was determined from carbon dioxide
equilibration. Sample tubes were ﬂushed
with 0.5% CO2 in helium and incubated
overnight at 22.5°C. Isotopic enrich-
ments were measured relative to labora-
tory standards that were previously
calibrated against the international stan-
dardsoftheViennaStandardMeanOcean
Water and Standard Light Arctic Precipi-
tation (International Atomic Energy
Agency, Vienna, Austria).
Plasma adiponectin, leptin and total
ghrelin, total peptide YY, and glucagon-
like peptide-1 concentrations were deter-
mined by radioimmunoassay (Millipore,
Billerica, MA). Plasma IGF-1 concentra-
tions were determined using a nonextrac-
tion immunoradiometric assay (Beckman
CoulterU.K.,HighWycombe,U.K.).Plasma
resistin and pancreatic polypeptide were
measured using an ELISA (Millipore).
Data analysis
Average 24-h total energy intake was
calculated fromthe fooddiaryassessment
by a fully qualiﬁed dietitian who was
blinded to which basal insulin the pa-
tient was taking. Diet-induced thermo-
genesis was calculated as the area under
the energy expenditure curve (3 h) dur-
ing the standard meal and converted to
daily diet-induced thermogenesis using
thetotaldailycalorieintakefromthefood
diary.
The
18Oa n d
2H elimination rates (kO
and kH) were determined from the slope
ofthenaturallogarithmofisotopeenrich-
ment as a function of time calculated by
linear regression. Total body water was
calculated as the average of the dilution
space for H2
18O corrected by 1.01 and
2H2O corrected by 1.04. Total daily CO2
production rate (rCO2) was calculated as
rCO2 = 0.4554 total body water (1.01 kO 2
1.04 kH). Total energy expenditure was
calculatedfromrCO2andrespiratoryquo-
tient, using the equation of de Weir (5).
The jackknife technique was used to cor-
rect for bias and to evaluate experimental
and analytical error. Total energy expen-
diture could only be calculated in 17
paired samples because of the insufﬁcient
urine-sample collection in ﬁve patients.
The Actiheart data were downloaded
at the end of each 5-day period, and ac-
tivity energy expenditure was calculated
using a branched chain equation model
(6,7). For postprandial hormone mea-
surements, the areas under the hormone
time curves were calculated using the
trapezoidalruleandcorrectedforbaseline
concentration.
Statistical analysis
Results are presented as means 6 SE. The
primary analysis was a comparison of
the insulin detemir and the NPH insulin
treatments, with respect to total energy
expenditure (including components of
energy expenditure, hormones, and
body composition), and separately, with
respect to 7-day food intake. In each case,
the data were analyzed with a general lin-
ear mixed model, with the subject as the
random effect and the study period and
treatment as ﬁxed effects, including a
treatment–by–study period ﬁxed-effect
interaction. For the comparison of the
same two treatments, using the hormone
response to a meal, measured at several
time points on each subject in each of the
two periods, the above analysis was mod-
iﬁed to additionally include a repeated-
measureeffectforthetimesofmeasurement.
The software used for these analyses was
t h eP R O CM I X E Dp r o c e d u r eo fS A Sv e r -
sion9.1(SASInstitute,Cary,NC).Structural
equation modeling also was performed,
using SAS PROC CALIS, to explore the
relationships between food and weight
andthehormonesmeasuredinthestudy.
RESULTS
Body weight
After 16 weeks of treatment, mean body
weight (Fig. 1) and fat-free mass were sig-
niﬁcantlylowerwith insulindetemir than
with NPH insulin (P = 0.0006; P =
0.0001). Fat mass was not signiﬁcantly
different between treatments (Table 1).
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Insulin detemir reduces food intakeGlycemic control
HbA1c at the end of 16 weeks of treat-
ment was not different between the two
treatments (Table 1). Statistical analysis
showed that glycemic control during the
two treatments could not explain the
signiﬁcant difference in weight (P =
0.617). There was no signiﬁcant dif-
ference in the number of hypoglycemic
episodes (,3.1 mmol/L) between the
twotreatments.Therewerenomajorhypo-
glycemic episodes (deﬁned as patients
unable to treat themselves) in the trial.
Insulin requirements
The total daily dose of insulin aspart did
not signiﬁcantly change in the insulin
detemirarm compared with the NPHarm
(35.8 6 3.66 vs. 34.3 6 3.11 IU/day; P =
0.32).The total daily dose of basal insulin
did not signiﬁcantly change with the in-
sulin detemir arm compared with the
NPH arm (27.9 6 3.2 vs. 26.7 6 2.76
IU/day; P = 0.33)
Energy intake and expenditure
Average daily food intake, measured us-
ing a 7-day food diary, was signiﬁcantly
lower with detemir compared with NPH
insulin (P =0.026).Thiswas attributed to
lower fat (P = 0.006) and protein (P =
0.01) intake, with no difference in carbo-
hydrate intake. Calorie intake during the
unlimited meal was not different between
detemir and NPH insulin.
Total, activity, and resting energy
expenditure and diet-induced thermo-
genesis were not signiﬁcantly different
between insulin detemir and NPH insulin
(Table1).Restingenergyexpenditurewas
negatively related to HbA1c (P = 0.023).
Hormone responses
Fasting plasma leptin was lower and
resistin was higher with insulin detemir
than with NPH insulin (P = 0.039; P =
0.047). There was no signiﬁcant differ-
ence in fasting adiponectin and IGF-1.
In response to a standard meal, ghrelin
and pancreatic polypeptide were higher
with insulin detemir than with NPH in-
sulin(P=0.002;P=0.001).Therewasno
signiﬁcant difference in glucagon-like
peptide-1and peptide YY levels(Table2).
Structured equational modeling
The modelshowedapositive relationship
betweenweightandleptin,betweenweight
and fat-free mass, and between weight
and pancreatic polypeptide (Fig. 2). Ad-
ditional negative relationships were ob-
served between food intake and leptin,
betweenresistinandleptin,betweenpan-
creaticpolypeptideandfat-freemass,and
between ghrelin and fat-free mass.
CONCLUSIONS—The current study
is consistent with previous studies that
showed treatment with insulin detemir
tobeassociatedwithlessweightgainthan
treatment with NPH insulin. There was
as i g n i ﬁcant difference in energy intake,
as assessed by a 7-day food diary. This
corresponded to an ~160 kcal/day differ-
ence between detemir and NPH insulin
and could explain the observed weight
difference betweentreatments duringthis
study. Total energy expenditure, as well
as its components, showed no differences
between insulin detemir and NPH insu-
lin. It is widely recognized that energy
expenditure decreases with weight loss.
Although the average difference in weight
between treatments at the end of the two
interventions was ~2.4 kg, total energy
expenditure was not different. Thus, a
small effect of detemir on total energy
expenditure cannot be excluded. Thus,
insulin detemir seems to mediate its
weight-sparing effects by altering energy
intake rather than energy expenditure.
It is well recognized that in patients
with diabetes (8), there is a signiﬁcant
underestimation of self-reported food in-
take, and this also was the case in this
study. However, because this was a cross-
over study, this would be expected to be
similar with both insulins. Macronutrient
composition analysis showed that the
decrease in food intake was a result of a
signiﬁcant reduction in protein and fat
intake. Itisnotablethatadecrease inpro-
tein intake also was shown in a study in-
vestigating the acute effects of insulin
detemir on food intake (9).
Various hypotheses have been put
forward to explain the weight-sparing ef-
fects of insulin detemir. Treatment with
insulin detemir has been shown to be as-
sociated with reduced blood glucose vari-
ability and a reduced risk of hypoglycemia
Figure 1—A: Changesinbodyweightafter16weeksoftreatment.B:Changeinenergyintakeafter
16weeks.C:Changeintotalenergyexpenditureafter16weeks.□,NPHinsulin;■,insulindetemir.
Table 1—Weight changes, energy expenditure, energy intake, and hypoglycemic episodes
during and at the end of the treatment periods with insulin detemir and NPH insulin
NPH insulin Insulin detemir P
Weight change over 16 weeks (kg) 1.7 6 0.52 20.69 6 0.39 ,0.001
Fat mass change over 16 weeks (kg) 0.42 6 0.380 0.16 6 0.45 0.562
Fat-free mass change over 16 weeks (kg) 1.26 6 0.31 20.9 6 0.25 ,0.001
Energy intake (kcal/day) 2,181 6 122.1 2,018 6 109.4 0.02
Carbohydrate (g/day) 237.43 6 15.02 225.2 6 15.69 0.203
Fat (g/day) 82.59 6 5.3 69.04 6 4.45 0.006
Protein (g/day) 85.11 6 5.57 76.6 6 4.11 0.01
Calorie intake during unlimited meal (kcal) 871 6 74.6 823 6 85.5 0.523
Total energy expenditure (kcal/day) 3,233 6 236.9 3,074 6 301.5 0.334
Resting energy expenditure (kcal/day) 2,034 6 78.6 1,932 6 94.5 0.312
Resting energy expenditure (kcal/day/kg) 24.4 6 0.99 23.6 6 1.21 0.522
Activity energy expenditure (kcal/day) 542.7 6 61.4 588.5 6 76.4 0.566
Diet-induced thermogenesis (kcal/day) 74.2 6 7.22 73 6 7.4 0.777
HbA1c (%) 7.5 6 0.26 7.8 6 0.23 0.061
Hypoglycemic episodes 4.9 6 1.53 4.6 6 1.58 0.586
Data are means 6 SE. Boldface type indicates P values that are statistically signiﬁcant (P , 0.05).
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JULY 2011 1489
Zachariah and Associatescompared with treatment with NPH in-
sulin (10). This might imply that patients
are avoiding weight gain by reducing
their “defensive snacking.” The basal ana-
log insulin glargine has consistently re-
duced hypoglycemia compared with
NPH insulin, but most trials (11,12) that
have reported weight data do not show
reduced weight gain with this analog. In
the current study, additional statistical
analysis showed that the weight differ-
ence could not be explained by a differ-
ence in glycemic control or hypoglycemic
episodes.
Another putative mechanism for the
weight-lowering effect of insulin detemir
concerns the blood glucose–lowering
action of this analog (13). A relatively
greater percentage of the total blood
glucose–loweringeffectofinsulindetemir
is derived from its hepatic action, com-
pared with that of exogenous human in-
sulin delivered into the subcutaneous
and systemic circulation (14,15). This
could result in a relative reduction of pe-
ripheral lipogenesis, preventing weight
gain (14). It has been suggested that the
reversible albumin-binding property of
insulindetemirlimits access to peripheral
tissues through the endothelial barrier,
while allowing full access to hepatocytes
via the large sinusoidal fenestrae in
hepatic capillary membranes. The slight
hepatoselective effect seen with insulin
detemir may thus reduce free fatty acid
deposition and glucose uptake into pe-
ripheral tissues. It has been demonstrated
that the partitioning of fuels among dif-
ferent tissues and between metabolic
pathways has signiﬁcant effects on food
intake (16). This may be via ATP produc-
tion or may be caused by changes in sati-
ety factors, such as leptin and ghrelin.
Although there was a decrease in fasting
leptin, an increase in resistin, and an in-
crease in the ghrelin response to a meal,
these changes could be a consequence
rather than a cause of weight loss (17).
In humans, an infusion of pancreatic
polypeptide (PP) was shown to reduce
acute food intake at a buffet meal 2 h after
the infusion and reduce food intake for
the following 24 h (18). PP-binding sites
have been demonstrated in the area post-
rema, and the activation of neurons in the
area postrema after PP administration
suggests that PP has a central effect on
satiety (19). The observed increase of PP
in the insulin detemir–treated patients is
of considerable interest, and the mecha-
nism is unknown.
An alternative mechanism that has
been proposed is that insulin detemir
may act directly on the brain to affect
appetite. Insulin receptors are abundant
in parts of the brain, including the hypo-
thalamus (20), where insulin is involved
in the regulation of satiety and appetite
(21). Preliminary studies (22,23) have re-
ported that the effect of human insulin on
cerebrocortical activity is compromised
in obese patients, whereas the effect of
insulindetemirisenhanced.Insulindetemir
may have a tissue-selective action, with a
relative preference for brain compared
with peripheral tissues. A recent study (9)
showed that while inducing comparable
peripheral effects, insulin detemir, com-
paredwithhumaninsulin,hadanenhanced
anorexigenic impact on the central nervous
system that controls nutrient uptake.
The design of this crossover study
allowed a statistical exploration of the
relationships between changes in the
measured variables using structural equa-
tion modeling. The mathematical model
that was developed conﬁrms known
physiological relationships between food
intake, weight, and leptin and between
weight and fat-free mass. The negative
relationship between ghrelin and fat-free
mass also conﬁr m sp r e v i o u ss t u d i e s
(24,25). A negative relationship between
pancreatic polypeptide and fat-free mass
has not previously been reported.
A limitation of the study is that it was
an open-label design and the fact that test
subjectsknewtheywereoninsulindetemir,
which has been widely advertised to cause
less weight gain, might be a confounding
factor.
In conclusion, this study shows that a
relative reduction in weight gain associ-
ated with insulin detemir therapy versus
NPH insulin is attributed to a reduction
in calorie consumption. This effect might
bemediated by a direct effect on thebrain
or by an indirect effect on satiety as a re-
sultof thehepatoselectiveeffect ofinsulin
detemir modulating orexigenic and an-
orexigenic hormones.
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